Idera Pharmaceuticals to Provide ILLUMINATE-204 Clinical Data Update on Friday, December 14, 2018


EXTON, PA — Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs, today announced that it plans to release an update on clinical data from the ongoing Phase 2 trial of the combination of intratumoral tilsotolimod and ipilimumab for unresectable or metastatic melanoma following failure of anti-PD-1 inhibitor treatment prior to the opening of the U.S. financial markets on Friday, December 14, 2018.

The company will host a conference call and live webcast, Friday, December 14 at 10:00 A.M. EST to review the data being presented along with a questions and answers session.

Investor Webcast Details
To participate in the conference call, dial (844) 882-7837 (domestic) and (574) 990-9824 (international).  The webcast can be accessed live or in an archived form in the “Investors” section of the company’s website at  The company will be posting a slide presentation to the Idera corporate website in the “Investors” section which will be referenced during the conference call.

READ:  Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Live audio webcast of Idera’s presentations will be accessible in the Investors and Media section of Idera’s website at  Archived versions will also be available on the Company’s website after the event for 90 days.

Source: Idera Pharmaceuticals, Inc., 505 Eagleview Blvd, Exton PA 19341

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.

Buy Us a Cup of Coffee